Amorphous telithromycin compound
    3.
    发明授权
    Amorphous telithromycin compound 失效
    无定型泰利霉素化合物

    公开(公告)号:US08222380B2

    公开(公告)日:2012-07-17

    申请号:US12159939

    申请日:2007-01-04

    IPC分类号: C07H17/08

    CPC分类号: C07H17/08

    摘要: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

    摘要翻译: 本发明涉及稳定的无定形3-De [(2,6-二脱氧-3-C-甲基-3-O-甲基-α-L-核糖-6-吡喃糖基)氧基] -11,12-二脱氧-6-O-甲基 -3-氧代-12,11- [氧羰基[[4- [4-(3-吡啶基)-1H-咪唑-1-基]丁基]亚氨基]]红霉素(泰利霉素),其制备方法, 稳定的非晶泰利霉素治疗细菌感染和包含稳定的非晶泰利霉素的药物组合物。

    ORGANIC COMPOUNDS
    5.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号:US20110015191A1

    公开(公告)日:2011-01-20

    申请号:US12528483

    申请日:2008-02-22

    CPC分类号: C07D413/06

    摘要: Novel polymorph form III of Aprepitant and a method for preparation of novel form III is disclosed. New processes for the preparation of Aprepitant form II are disclosed. The processes involve transformation of form III to form II by heating in decalin and the precipitation of form II from a solvent or solvent mixture by cooling and/or addition of addition of seed crystals or an anti solvent. Solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A process for the preparation of the solid dispersion by evaporation of a solution of Aprepitant and the carrier in a suitable solvent is disclosed. Stable Aprepitant form II is disclosed. Further pharmaceutical compositions containing Aprepitant form II, III or solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A methanol solvate of Aprepitant is disclosed.

    摘要翻译: 公开了Aprepitant的新型多晶型III和新型III的制备方法。 公开了制备Aprepitant II型的新方法。 所述方法包括通过在十氢化萘中加热和通过冷却和/或加入晶种或抗溶剂从溶剂或溶剂混合物中沉淀形式II而转化成形式II。 公开了在合适的载体中含有形式II的固体分散体。 公开了通过在适当溶剂中蒸发阿维地丁和载体溶液来制备固体分散体的方法。 公开了稳定的Aprepitant II型。 公开了另外的药物组合物,其中含有Aprepitant形式II,III或在合适的载体中含有Aprepitant II型的固体分散体。 公开了一种甲酸溶剂化物的Aprepitant。

    Polymorphs of an active pharmaceutical ingredient
    10.
    发明授权
    Polymorphs of an active pharmaceutical ingredient 有权
    活性药物成分的多晶型物

    公开(公告)号:US08946441B2

    公开(公告)日:2015-02-03

    申请号:US13702077

    申请日:2011-06-24

    CPC分类号: C07D277/56

    摘要: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.

    摘要翻译: 本发明涉及非索非斯坦的结晶形式I以及包含结晶形式I作为活性药物成分的药物组合物。 此外,本发明还涉及另一种指定为II型的异丙酚钠的多晶型物,还涉及一种新颖的非索非司他溶剂合物。 本发明还涉及制备结晶形式I,形式II和新戊酸钠的新型溶剂合物的方法。